Abstract. Ovarian carcinomas can progress through two pathways of genomic instability: chromosomal instability (CIN) and microsatellite instability (MSI). However, it is unknown whether these two mechanisms could be distinguished from each other in the molecular characteristics in ovarian carcinomas. We hypothesized that these two pathways are not always independent in ovarian carcinomas. We classified 51 ovarian carcinomas based on their MSI and CIN status using microsatellite analysis and assessed whether these carcinogenic pathways affect the clinicopathological features and patient survival. Of the 51 cases, 77.4% of the tumors were microsatellite stable (MSS), 5.9% were MSI-Low (MSI-L) whilst, 16.7% were MSI-High (MSI-H). Overall, 56.8% of the tumors had at least one loss of heterozygosity (LOH) event, i.e., 56.8% CIN. Notably, we identified a significant degree of overlap between the MSI and CIN pathways. Of the 34 tumors with LOH events (CIN), 5 (14.7%) were MSI-H. In addition, of the 7 tumors that were MSI-H, 5 (71.4%) had one or more LOH events (CIN). We also identified a group of 29.4% of all tumors that did not demonstrate any evidence of either of the two pathways of genomic instability as they were MSS/MSI-L with no evidence of LOH events (CIN negative). Furthermore, patients with CIN with MSS/MSI-L have a significantly shorter overall survival compared to those in other genetic categories (P=0.019). Cox regression analysis revealed that tumors with CIN with MSS/MSI-L exhibit a poor prognostic outcome after adjustment for FIGO stage and grade. These findings suggest that some ovarian carcinomas have a significant degree of overlap between the two pathways of genomic instability and that the genetic classification using microsatellite markers may represent a potential new biomarker of risk prediction in ovarian carcinoma.
Introduction
Ovarian carcinoma is the most lethal gynecological malignancy at present (1) . Women with organ-confined tumors have an excellent prognosis, whereas the overall survival of the majority of ovarian carcinoma patients with advanced disease is <30% (2, 3) . Despite the development of new therapeutic approaches, these survival statistics have remained largely unchanged for many years. Clearly, there is a need for a better understanding of the molecular pathogenesis of ovarian carcinoma so that new drug targets or biomarkers that facilitate risk prediction can be identified.
Ovarian carcinogenesis is characterized by the successive accumulation of mutations in genes controlling epithelial cell growth and differentiation. The term 'genomic instability' describes conditions in which widespread loss of DNA integrity is perpetuated. The development of genomic instability is an important event in the multistep progression of ovarian carcinogenesis. Two apparently independent pathways of genomic instability have been identified (4, 5) . The first, and more common pathway is characterized by the sequential inactivation of tumor-suppressor genes, such as p53 (chromosome 17p), BRCA1 (chromosome 17q) and FHIT (chromosome 3p). Tumors generated through this ONCOLOGY REPORTS 19: 775-781, 2008 775 Genetic classification of ovarian carcinoma based on microsatellite analysis: Relationship to clinicopathological features and patient survival ZHANG HUAN 1, 4 , KENTARO NAKAYAMA 1 , NAOMI NAKAYAMA 1 , MASAKO ISHIBASHI 1 ,
'suppressor' pathway display chromosal instability (CIN) with frequent cytogenetic abnormalities and allelic losses (6, 7) . The precise mechanism driving the process of chromosomal instability is not completely understood. A second pathway is characteristic of tumors from patients with HNPCC, an autosomal-dominat condition that accounts for 2-3% of all colorectal carcinomas. The hallmark of this alternative 'mutator' pathway is widespread microsatellite instability (MSI), which is characterized by the accumulation of somatic alterations in the length of simple, repeated nucleotide sequences called 'microsatellites'. Microsatellite instability (MSI) is also seen in a significant proportion of extracolonic tumors including breast, endometrial (8) , gastric (9) , and ovarian carcinoma (10) (11) (12) . MSI-H has also been identified in 3-10% of sporadic solid carcinomas (13) . In these cases, mutations of hMLH1 and hMSH2 are rarely found. Some studies indicate that hMLH1 inactivation by promoter hypermethylation also produces the MSI-H phenotype in sporadic solid carcinomas and is responsible for most, if not all, of the sporadic solid carcinomas exhibiting MSI-H (14-16). MSI-H colorectal carcinomas do not exhibit gross cytogenetic abnormalities; and they are not generally aneuploid (17, 18) . Furthermore, patients with MSI-H tumors have a more favorable survival compared to patients with MSI-L/MSS solid carcinomas (13, 19, 20) .
Although these two mechanisms of genomic instability can be distinguished from one another by their molecular characteristics, current evidence suggests that there might be some degree of overlap. Recently, Goel et al reported that there is a significant degree of overlap between the MSI and CIN pathways in colorectal carcinomas (21) . To date, no systematic study has determined the extent of overlap between the MSI and CIN pathways in ovarian carcinomas. The present study was therefore pursued in order to classify ovarian carcinomas based on their MSI and CIN status. We hypothesized that some tumors would exhibit a significant degree of overlap between these two mechanisms, whilst a proportion of tumors might not show any evidence for involvement of either mutational pathways. In addition, we assessed whether evidence of these carcinogenic pathways was related to clinicopathological features and patient survival.
Materials and methods
Patients and tumor samples. Fifty-one ovarian carcinomas and their adjacent non-neoplastic tissues were obtained from archival pathological specimens from the Shimane University Hospital in Japan. Written informed consent for the analysis in this study was obtained for each individual case. Acquisition of tissue specimens was approved by the Institutional Review Board at Shimane University. Diagnostic verification, tumor subtyping and grading were performed independently by two certified pathologists (R.M. and M.F.). Ovarian carcinomas were diagnosed on the basis of conventional histopathological criteria (22) , using the grading criteria recommended by the International Federation of Gynecology and Obstetrics.
The series of tumor tissues included in the study consisted of 20 serous, 17 
DNA extraction using microdissection and PCR amplification.
Paraffin-embedded tissues were sectioned at a thickness of 5 μm and stained with hematoxylin and eosin. The cancerous and non-neoplastic portions were collected separately with a 29-gauge needle using an MK1 micromanipulator (Singer Instruments, Roadwater, UK) under a dissecting microscope. The dissected tissue was collected in an Eppendorf tube and incubated overnight at 58˚C in a digestion mixture (0.01 M NaCl; 0.5 M Tris-HCl, pH 8.0; 20 mM EDTA; 0.05% Tween-20 ® ; 0.1 mg/ml proteinase K). The samples were then heated to 95˚C for 10 min to inactivate the proteinase K activity. After digestion, DNA was extracted with phenol/ chloroform treatment and ethanol precipitation. PCR reactions were performed in a total volume of 10 μl containing 25-50 ng of DNA, dNTPs at a final concentration of 20 μM, 0.4 μM of each primer, and 0.25 units of Ex-Taq DNA polymerase (Takara Shuzo, Shiga, Japan) or Platinum Taq DNA polymerase (Gibco Brl, Rockville, MD). After the mixture was heated for 10 min at 94˚C, PCR was performed for 45 cycles at 94˚C, at the appropriate annealing temperature and at 72˚C for 1 min each, followed by 72˚C for 10 min. After denaturation of the PCR products at 94˚C for 2 min, samples were subjected to electrophoresis using Performance optimized polymer 4 in a 310 Genetic analyzer (Applied Biosystems, Foster, CA). LOH analysis was performed by Gene Scan version 2.1.
Microsatellite markers and MSI analysis. Allelic imbalances
were measured by performing MSI on all matched normal and tumor tissues by PCR amplification. A panel of eight microsatellite markers with dye-labeled primers, comprising of 7 dinucleotide repeats (D2S123, D5S346, D8S87, D13S153, D13S175, D18S55, D20S100) and, 1 mononucleotide repeat (BAT25) were used to determine tumor MSI status. These markers included the recommended markers for the detection of MSI proposed at the National Cancer Institute collaborative meeting on MSI in colorectal carcinoma (23) . Loci were scored according to the published guidelines. Changes in the electrophoretic mobility of DNA amplified by PCR were used to assess the MSI. We defined tumors as exhibiting MSI if they had at least 1 locus with MSI among cases in which PCR was successful on more than five loci. Among tumors exhibiting MSI, cases with >30% of loci showing MSI were defined as MSI-H and the remaining cases were designated MSI-L. Tumors not demonstrating allelic shifts were termed as MSS (Fig. 1) .
Microsatellite markers and LOH analysis. Eight sets of polymorphic microsatellite sequences that are tightly linked to known tumor suppressor genes and markers reported to be associated with ovarian carcinoma were used to identify significant allelic losses in the carcinoma specimens. DNA was amplified by PCR using dye-labeled primers at microsatellite loci linked to the FHIT locus on 3p21.2-14.2 (D3S1306), p53 locus on 17p13 (TP53), BRCA1 locus on 17q21 (D17S579), 6q25 (D6S473), 7q31 (D7S523), 9q31-33 (D9S59), 11p15.5-15.3 (D11S988) and Xq11-12 (AR). LOH was quantified by calculating the LOH index. This was defined as the allele ratio in normal tissue divided by the allele ratio in tumor tissue. The allele ratio was calculated as the peak height of the smaller allele divided by the peak height of the larger allele. If the LOH index was <0.5 or >2.0, we defined the case as LOH. The LOH frequency of each locus was represented by the ratio of the number of cases with LOH to the total number of informative cases.
Statistical analysis. Overall survival time was measured in months from the time of surgery to the reported death. Survival curves were determined using the Kaplan-Meier method and differences in survival between subgroups were compared with the log-rank test. P-values <0.05 were considered significant. All reported P-values are two-tailed.
Results
Microsatellite typing. Informative results were obtained for all tumor specimens. Of the 51 cases, 41 (77.4%) were MSS, 3 (5.9%) were MSI-L, and 7 (16.7%) were MSI-H (Table I) . MSI-L tumors were categorized along with MSS tumors for all statistical purposes in this study. MSI-H tumors correlated with both histological subtype and tumor grade. MSI-H tumors tended to be more frequent in endometrioid type tumors than in serous type tumors (P=0.07) ( Table I ). In addition, MSI-H tumors were significantly more frequent in well-differentiated carcinomas than in moderately/poorly differentiated carcinomas (P=0.02). MSI-H tumors were significantly more frequent in stage I, II tumors than in stage III, IV tumors (P=0.04).
LOH study. We identified 34 tumors (66.7%) with LOH at one or more of the eight loci studied. Overall, the frequency of LOH in tumors with any LOH event was most common in 17p13 (TP53) (46.3%), followed by 11p15.5-15.3 (D11S988) (38.7%), 3p21.2-14.2 (D3S1306) (34.8%), 9q31-33 (D9S59) (30.0%), 7q31 (D7S523) (29.4%), 6q25 (D6S473) (21.0%), Xq11-12 (AR) (15.0%) and 17q21 (D17S579) (13.2%). Based on the number of affected LOH, the LOH genotype was divided into 2 groups. Tumors with LOH in at least one of the eight markers were classified as exhibiting chromosomal instability (CIN) whilst tumors with no evidence of LOH were classified as CIN negative. Of the 53 cases, 34 (66.7%) were CIN positive and 17 (33.3%) were CIN negative (Table I) . CIN tumors were significantly more frequent in stage III, IV tumors than in stage I, II tumors (P=0.04). Table I . Association of microsatellite genotypes with clinicopathological features. - (Fig. 2) . We found that 9.8% of all tumors exhibited both MSI-H and CIN whilst, 4.0% were negative for both MSI-H and CIN. In addition, 56.8% of the MSS/MSI-L tumors were CIN negative. It is noteworthy that we identified a group comprising of 29.4% of all tumors examined that were MSS/MSI-L and CIN negative and therefore did not demonstrate signs of either of the two pathways of genomic instability (Fig. 2) .
Correlation between status of genomic instability and clinicopathological features.
Comparisons of the clinical and pathological variables of these four tumor categories are provided in Table II Analysis of survival rate. To verify whether a specific genomic instability exhibits a preferential association with more or less (Fig. 3A) . However, patients with MSS/MSI-L without CIN tended to have a more favorable overall survival compared with other genetic categories (P=0.151) (Fig. 3B) . No statistically significant difference was evident in the survival curves of patients with the other two genetic classifications (P=0.644 and 0.838, respectively). To determine whether CIN-positive tumors with MSS/MSI-L were a prognostic marker independent of FIGO stage or histological grade established prognostic markers, we conducted an overall survival analysis using the Cox proportional hazards model (Table III) . FIGO stage (hazard ratio: 7.0, 95% CI: 1.2-38.7, P=0.027) and CIN with MSS/MSI-L (hazard ratio: 2.5, 95% CI: 1.0-6.0, P=0.042) were independent prognostic factors in patients with ovarian carcinoma (Table III) .
Discussion
Our current understanding of solid tumor carcinogenesis, including ovarian carcinoma suggests that at least two mechanisms are capable of producing the mutations required for a cell to demonstrate a malignant phenotype. These mechanisms include CIN, characterized in tumor DNA by the presence of multiple LOH events, and loss of MMR function that is defined by high levels of MSI. In the current study, we examined 51 cases of ovarian carcinoma to determine whether ONCOLOGY REPORTS 19: 775-781, 2008 779 Table III . Multivariate analysis of overall survival in ovarian carcinoma patients. Table II . Correlation between status of genomic instability and clinicopathological features. 
these two mechanisms of tumorigenesis operated independently or whether there exists a significant degree of overlap.
We defined tumors as MSI if they had at least 1 locus with MSI among cases in which PCR was successful at more than 5 loci. Among MSI tumors, cases with >30% of loci showing MSI were defined as MSI-H and the remaining cases were designated MSI-L. Some studies suggest that the molecular profiles of MSS and MSI-L tumors are indistinguishable (24, 25) and we therefore, categorized MSI-L tumors with MSS tumors for all statistical purposes. To investigate allelic losses by LOH, we used eight polymorphic markers mapped closely to key tumor suppressor genes that are believed to be lost during ovarian carcinogenesis (26) (27) (28) (29) (30) (31) (32) . Detection of LOH in at least one of these sites was taken as evidence of loss of tumor suppressor activity by CIN. We accept that it is possible and even likely that tumors may well be reclassified by the addition of markers outside the usual deletion sites. However, without a single LOH event at the eight sites examined, it is highly unlikely that a tumor would exhibit widespread LOH that is characteristic of tumors arising in the setting of CIN. With these data, we classified the tumors as belonging to one of four genotypes: CIN with MSS/MSI-L; CIN with MSI-H; MSI-H without CIN and MSS/MSI-L without CIN.
MSI-H without CIN was found in 4% of the tumors analyzed. MSI-H is caused by a defect in DNA MMR capability which is most commonly caused by hypermethylation of the hMLH1 promoter (33) . Carcinomas associated with MMR defect are typically diploid, although comparative genomic hybridization shows that these tumors may also demonstrate amplifications and deletions of single alleles or chromosomes (34) . In agreement with this, 9.8% of the tumors in our study exhibited both MSI-H and CIN. CIN, as evidenced by allelic loss at one or more of the eight markers tested, was observed in 66.7% of the tumors examined. Tumors that exhibited LOH without MSI-H comprised 56.8% of the tumors. The presumed course of tumor progression in this subset involves accumulated allelic losses at the tumor suppressor loci (4). The processes responsible for CIN are unknown. Many mechanistic explanations have been offered for CIN, but none have been shown to be sufficient to account for this process in solid tumor carcinogenesis (7, 35, 36) . It is likely that multiple causes of CIN will be discovered through the study of these and other events in early carcinogenesis.
The most intriguing subgroup identified in this study was the 29.4% of ovarian carcinomas that lacked any evidence of either CIN or MSI. The molecular events leading to the development of carcinomas in this subgroup with no signs of genomic instability are unknown. One reasonable possibility is the transcriptional silencing of growth and differentiation genes by epigenetic modification. Aberrant promoter methylation, leading to loss of the tumor suppressor function, has been observed in a variety of cancers (37) . Epigenetic modification of tumor suppressor genes is characteristically age dependent (38) and there are several reports in the literature regarding tumor-specific methylation patterns (39) . We are in the process of characterizing the MSS/MSI-L without CIN subset using methylation-specific PCR.
We then assessed whether these carcinogenic pathways as discussed above, affect the clinical prognosis. It is well accepted that clinical stage is the most reliable guide to a prognosis. A biomarker might provide additional prognostic information if it were directly linked to a mechanism driving invasion and metastasis. Many investigators reported that MSI solid carcinomas are associated with an improved prognosis (13, 19, 20) , but the reasons are unclear (40) . In the current study, MSI ovarian carcinomas had no influence on patient survival (P=0.421). The emergence of carcinoma cells that are resistant to cisplatin and carboplatin is a major clinical problem and often leads to tumor recurrence (41) . Ovarian carcinoma cell lines that develop resistance to cisplatin have been found to acquire an MSI-H phenotype (42). Therefore, MSI-H ovarian carcinomas might not be associated with an improved prognosis in this study because all ovarian carcinoma patients in this study received cisplatin based chemotherapy.
One of the most statistically significant findings in our study was that patients with CIN with MSS/MSI-L ovarian carcinomas had a poor prognosis. CIN can be interpreted as indicating a high level of deleted chromosomal regions, aberrant mitotic recombinations, or nondisjunctional chromosomal loss (43) . In addition, it is also possible that some of the allelic imbalances we observed were due to the amplification of certain chromosomal regions. While genetic instability has generally been considered to be a characteristic feature of malignancy, it is still a matter of debate whether this instability is causally related to carcinogenesis or merely the result of other cellular events. Recent studies of colon carcinoma cells exhibiting CIN indicated that the CIN phenotype appeared to be a causative factor for tumor development, and may result from defects in proteins participating in mitotic checkpoint control (6) . The striking association between tumors with CIN with MSS/MSI-L and a poor prognosis, as observed in our study, may be explained by the possibility that CIN reflects an aggressive tumor phenotype. Our findings appear to fit the concept that specific types of genetic instability exist, and that this instability has a role in driving tumor development and progression (44) .
In summary, we reported that some ovarian carcinomas have a significant degree of overlap between the two pathways of genomic instability: CIN and MSI. The results of our study suggest that microsatellite typing is a useful tool for the construction of a comprehensive genetic classification that aims to predict the diverse clinical prognosis. A genetic classification using microsatellite markers may represent a potential new biomarker of risk prediction in ovarian carcinoma.
